1. Statin Class in Session

3. Program Goals

4. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

5. Dyslipidemia and Risk for Diabetes

6. How Statins Could Impair Glucose and Insulin Metabolism

7. Risk for New-Onset Diabetes With Statins Increases With Age

8. Additive Effect of Fasting Glucose and Statin Intensity on Risk for New-Onset Diabetes

9. Risk for Diabetes Based on Risk Factors and Statin Dose

10. Genetics of HMGCR AND PCSK9 Suggest New-Onset Diabetes is On-Target Effect

11. Risk for New-Onset Diabetes: Meta-Analysis of Placebo-Controlled Statin Trials

12. Changes in LDL-C and Glycemia in Head-to-Head Statin Trials

13. INTREPID Study: Impact of Pitavastatin and Pravastatin on Mean Fasting Glucose and HbA1c

14. Pitavastatin Has a Neutral Effect on FBG in Non-Diabetic Subjects Across the Dose Range

15. Pitavastatin Does Not Increase New-Onset Diabetes

16. Ezetimibe Lowers LDL-C Without Increasing Risk for New-Onset Diabetes

17. NLA Recommendations for Managing Dyslipidemia

18. Guideline Updates on the Use of PCSK9 Inhibitors

19. 2017 AACE Lipid Guidelines

20. Interprofessional Team Approach: Increase Efforts to Prevent Diabetes

21. Take-Home Messages

22. Abbreviations

23. Abbreviations (cont)